BioNTech (BNTX) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed BioNTech (BNTX) over the past year, gaining 290.0% versus a loss of 10.2%. Over five years, IBRX leads with a +4.8% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.19 billion vs $10.31 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | IBRX |
|---|---|---|
| Share price | $92.30 | $9.73 |
| Market cap | $23.19B | $10.31B |
| 1-day change | -3.10% | -0.26% |
| YTD return | +0.05% | +392.42% |
| 1-year return | -10.19% | +290.00% |
| 5-year return | -61.54% | +4.84% |
| EPS (TTM) | $-7.83 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $113.29M |
| Revenue growth (YoY) | — | +668.31% |
| Net income (latest FY) | — | $-351.40M |
| Gross margin | — | 99.34% |
| Operating margin | — | -226.00% |
| Net margin | — | -310.18% |
| 52-week high | $124.00 | $12.43 |
| 52-week low | $79.52 | $1.95 |
| Distance from 52-week high | -25.56% | -21.76% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.45% | +31.11% |
| Average volume | 1.15M | 10.29M |
| Shares outstanding | 251.20M | 1.06B |
| Employees | 7,807 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.2 times larger than ImmunityBio by market value ($23.19B vs $10.31B).
- IBRX has outperformed BNTX by 300.2 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
BNTX vs IBRX FAQ
Which is bigger, BioNTech or ImmunityBio?
BioNTech (BNTX) is larger, with a market capitalization of $23.19B compared with $10.31B for ImmunityBio (IBRX).
Which stock has performed better over the past year, BNTX or IBRX?
IBRX returned +290.00% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and ImmunityBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.